Oclacitinib (monomaleate), CAS 1640292-55-2

Product Description: Oclacitinib maleate (PF-03394197 maleate) is a novel JAK inhibitor. Oclacitinib maleate (PF-03394197 maleate) is most potent at inhibiting JAK1 (IC50=10 nM).

Applications: COVID-19-immunoregulation

Formula: C19H27N5O6S

References: [1]Gonzales AJ, et al. Oclacitinib is a novel Janus kinase inhibitor with activity against cytokines involved in allergy. J Vet Pharmacol Ther. 2014 Aug;37(4):317-24./[2]Fukuyama T, et al. Topically Administered Janus-Kinase Inhibitors Tofacitinib and Oclacitinib Display Impressive Antipruritic and Anti-Inflammatory Responses in a Model of Allergic Dermatitis. J Pharmacol Exp Ther. 2015 Sep;354(3):394-405./[3]Cosgrove SB, et al. Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis. Vet Dermatol. 2013 Oct;24(5):479-e114.

CAS Number: 1640292-55-2

Molecular Weight: 453.51

Compound Purity: 99.63

Research Area: Inflammation/Immunology

Solubility: DMSO : 250 mg/mL (ultrasonic)/H2O : 25 mg/mL (ultrasonic)

Target: JAK

• SKU: MEXHY-13577A-10.1
• Manufacturer: MedChemExpress
• Manufacturer SKU: HY-13577A-10.1
• Package Unit: 10 mM/1 ml
• Quantity Unit: STK